SCINUS HOLDING BV

Their core work

SCINUS HOLDING BV is a Dutch biotech SME specializing in cell expansion technologies and advanced cell therapy manufacturing. Their core work centers on developing scalable, xenofree (animal-product-free) processes for growing and deploying therapeutic cells — from muscle precursor cells to induced pluripotent stem cells (iPSCs). In practice, this means they contribute the manufacturing know-how that turns laboratory cell research into clinically viable treatments. Their project footprint spans two distinct but complementary disease areas: urological cell therapy and musculoskeletal regenerative medicine.

What they specialise in

How they've shifted over time

In their first H2020 project (MUSIC, from 2017), SCINUS focused tightly on a specific clinical problem — stress urinary incontinence — using muscle precursor cells and xenofree manufacturing to build a cell therapy pipeline. By 2019, with iP-OSTEO, their technological frame expanded substantially: the keywords shift from primary cells to iPSCs, from single-cell types to scaffolded 3D systems, and from a single disease to the broader terrain of musculoskeletal ageing (osteoporosis, osteoarthritis). The trend is a deliberate move up the technological complexity ladder, from established cell therapy manufacturing toward iPSC-based platforms that can theoretically address a wider range of degenerative diseases.

SCINUS is transitioning from single-disease cell therapy manufacturing toward a more platform-oriented iPSC and scaffold technology that could serve multiple musculoskeletal and age-related indications — making them an increasingly versatile partner for regenerative medicine consortia.

How they like to work

SCINUS participates exclusively as a consortium partner, never as coordinator — consistent with an SME that brings a specialized manufacturing or technology capability rather than leading broad research programs. Their two projects involved 19 unique partners across 11 countries, which is a notably wide network for just two participations and suggests they are valued connectors in European regenerative medicine circles. This breadth across partners and countries, without repetition, indicates they actively seek new collaborations rather than cycling through a fixed consortium.

SCINUS has collaborated with 19 unique partners across 11 countries through only two projects, indicating unusually broad network exposure per project. Their partnerships span both the MSCA mobility and RIA research tracks, suggesting connections across academic, clinical, and industrial communities in Europe.

What sets them apart

SCINUS occupies a specific niche that few SMEs fill: they combine cell expansion manufacturing know-how with direct participation in clinical-application research, meaning they understand both the production constraints and the end therapeutic context. Their xenofree manufacturing focus is commercially significant — regulatory pressure is pushing cell therapy products away from animal-derived reagents, and SMEs with proven xenofree protocols are in short supply. For a consortium building a cell therapy or regenerative medicine project, SCINUS brings not just scientific expertise but translatable manufacturing readiness.

Highlights from their portfolio

• MUSIC
  Their largest project by far at nearly EUR 1M, MUSIC tackled the full cell therapy pipeline for urinary incontinence — from xenofree muscle precursor cell manufacturing to neuromuscular stimulation — making it their most commercially grounded and clinically proximate work.
• iP-OSTEO
  Despite modest direct funding (EUR 32,200 as an MSCA-RISE mobility project), iP-OSTEO signals a deliberate strategic pivot into iPSC technology and nanofibrous scaffolds for bone and cartilage repair, targeting the large and growing market for osteoporosis and osteoarthritis treatments.